Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OmniAb Inc. (OABI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/21/2025: OABI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -40.93% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 294.95M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 532111 | Beta 0.35 | 52 Weeks Range 2.23 - 5.54 | Updated Date 04/1/2025 |
52 Weeks Range 2.23 - 5.54 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-18 | When After Market | Estimate -0.0967 | Actual -0.12 |
Profitability
Profit Margin -235.05% | Operating Margin (TTM) -146.57% |
Management Effectiveness
Return on Assets (TTM) -13.71% | Return on Equity (TTM) -20.6% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 257464533 | Price to Sales(TTM) 11.18 |
Enterprise Value 257464533 | Price to Sales(TTM) 11.18 | ||
Enterprise Value to Revenue 9.76 | Enterprise Value to EBITDA -10.62 | Shares Outstanding 122135000 | Shares Floating 99561961 |
Shares Outstanding 122135000 | Shares Floating 99561961 | ||
Percent Insiders 6.03 | Percent Institutions 67.65 |
Analyst Ratings
Rating 4.75 | Target Price 9.62 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
OmniAb Inc.
Company Overview
History and Background
OmniAb, Inc. (formerly Ligand Pharmaceuticals) is a biopharmaceutical company specializing in antibody discovery. It provides biopharmaceutical companies with access to its transgenic animal platforms to discover and develop novel therapeutic antibodies. While originating as part of Ligand, it has since spun-off to operate independently. Significant milestones include the development and refinement of its OmniAb platform and collaborations with numerous pharmaceutical partners.
Core Business Areas
- Antibody Discovery Platforms: OmniAb provides access to its proprietary transgenic animal platforms (OmniRat, OmniMouse, OmniChicken, OmniFlic, and OmniTaur) that generate fully human antibodies. These platforms are used by partners for therapeutic antibody discovery.
- Partnerships and Licensing: OmniAb generates revenue primarily through licensing fees, milestone payments, and royalties based on the success of its partners' antibody programs.
Leadership and Structure
The leadership team consists of executives with experience in biopharmaceutical development and licensing. The organizational structure is designed to facilitate collaboration with partners and efficient operation of the antibody discovery platforms.
Top Products and Market Share
Key Offerings
- OmniRat: Transgenic rat platform for generating fully human antibodies with high affinity and specificity. No exact market share data is directly attributed to OmniRat. Competitors include companies offering alternative antibody discovery technologies and platforms. Sanofi, Regeneron, and AstraZeneca would be considered indirect competitors in antibody development.
- OmniMouse: Transgenic mouse platform for generating fully human antibodies, offering a complementary approach to OmniRat. No exact market share data is directly attributed to OmniMouse. Competitors include companies offering alternative antibody discovery technologies and platforms. Sanofi, Regeneron, and AstraZeneca would be considered indirect competitors in antibody development.
- OmniChicken and OmniFlic: Transgenic chicken and other animal platforms to generate fully human antibodies, offering a complementary approach to OmniRat and OmniMouse. No exact market share data is directly attributed to OmniChicken or OmniFlic. Competitors include companies offering alternative antibody discovery technologies and platforms. Sanofi, Regeneron, and AstraZeneca would be considered indirect competitors in antibody development.
- OmniTaur: Transgenic bovine platform for generating fully human antibodies, offering a complementary approach to OmniRat and OmniMouse. No exact market share data is directly attributed to OmniTaur. Competitors include companies offering alternative antibody discovery technologies and platforms. Sanofi, Regeneron, and AstraZeneca would be considered indirect competitors in antibody development.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing growth driven by increasing demand for novel therapeutics, particularly antibody-based drugs. Antibody discovery technologies play a critical role in enabling the development of these drugs.
Positioning
OmniAb is positioned as a leading provider of transgenic animal platforms for antibody discovery, offering a diverse range of species to maximize the chances of generating effective antibodies. Its competitive advantage lies in its breadth of platforms and the proven track record of its technology.
Total Addressable Market (TAM)
The total addressable market for antibody discovery technologies is estimated to be in the billions of dollars annually. OmniAb is positioned to capture a significant share of this market through its licensing and partnership agreements.
Upturn SWOT Analysis
Strengths
- Proprietary transgenic animal platforms (OmniRat, OmniMouse, OmniChicken, OmniFlic, and OmniTaur)
- Proven track record of successful antibody discovery
- Established partnerships with leading pharmaceutical companies
- Experienced leadership team
Weaknesses
- Dependence on partners' success for revenue generation
- High research and development costs
- Competition from other antibody discovery technologies
- Platform adoption uncertainty
Opportunities
- Expanding partnerships with pharmaceutical companies
- Developing new transgenic animal platforms
- Applying its technology to new therapeutic areas
- Growth in the antibody therapeutics market
Threats
- Competition from alternative antibody discovery technologies
- Failure of partners' antibody programs
- Changes in regulatory requirements
- Economic downturn affecting pharmaceutical R&D spending
Competitors and Market Share
Key Competitors
- LLY
- BMY
- AZN
- MRK
Competitive Landscape
OmniAb's advantages lie in its breadth of platforms and proven technology. Disadvantages include dependence on partners and competition from other technologies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends can be determined from past financial reports.
Future Projections: Future growth projections are based on analyst estimates and depend on the success of ongoing and future partnerships.
Recent Initiatives: Recent initiatives include expanding partnerships, developing new transgenic animal platforms, and pursuing new therapeutic areas.
Summary
OmniAb Inc. is a biopharmaceutical company specializing in antibody discovery. The company's strengths lie in its proprietary technology and established partnerships. A key risk is its dependence on the success of its partners' programs. OmniAb needs to continue expanding its partnerships and developing new platforms to sustain growth.
Similar Companies
AZN
AstraZeneca PLC ADR
AZN
AstraZeneca PLC ADR
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
Sources and Disclaimers
Data Sources:
- OmniAb Inc. SEC Filings
- OmniAb Inc. Investor Relations
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OmniAb Inc.
Exchange NASDAQ | Headquaters Emeryville, CA, United States | ||
IPO Launch date 2022-11-02 | President, CEO & Director Mr. Matthew W. Foehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 114 | Website https://www.omniab.com |
Full time employees 114 | Website https://www.omniab.com | ||
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.